End Points Must Be Clinically Meaningful for Drug Development in Nonalcoholic Fatty Liver Disease

Gastroenterology. 2016 Jan;150(1):11-3. doi: 10.1053/j.gastro.2015.11.017. Epub 2015 Nov 18.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Biopsy, Needle
  • Chronic Disease
  • Drug Discovery / methods*
  • Drugs, Investigational / pharmacology*
  • Female
  • Humans
  • Immunohistochemistry
  • Magnetic Resonance Imaging / methods
  • Male
  • Needs Assessment
  • Non-alcoholic Fatty Liver Disease / diagnosis*
  • Non-alcoholic Fatty Liver Disease / drug therapy*
  • Severity of Illness Index
  • United States

Substances

  • Drugs, Investigational